Skip to main content
. 2023 Dec 8;109(2):202–213. doi: 10.1113/EP091566

FIGURE 1.

FIGURE 1

Schematic representation of a cardiomyocyte under normal conditions (a), during systemic treatment with acipimox (b, a lipid lowering agent), during 48‐h fasting (c), and in response to a whole‐body hyperglycaemic–hyperinsulinaemic clamp (d). FA, free fatty acids; G‐6‐P, glucose‐6‐phosphate; GLUT, glucose transporter; TG, triglyceride.